Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM-1: ITCA 650 in Type 2 Diabetes
NCT01455857Phase 3Completed
- Sponsor
- Intarcia Therapeutics
- Start
- Mar 2013
- Primary completion
- Aug 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Intarcia Therapeutics. Started Mar 2013; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01455857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455857.